Haematologica (Aug 2023)

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

  • Jan Frederic Weller,
  • Claudia Lengerke,
  • Jürgen Finke,
  • Johannes Schetelig,
  • Uwe Platzbecker,
  • Hermann Einsele,
  • Thomas Schroeder,
  • Christoph Faul,
  • Matthias Stelljes,
  • Peter Dreger,
  • Igor W. Blau,
  • Gerald Wulf,
  • Johanna Tischer,
  • Christoph Scheid,
  • Ahmet Elmaagacli,
  • Helga Neidlinger,
  • Sarah Flossdorf,
  • Martin Bornhäuser,
  • Wolfgang Bethge,
  • Katharina Fleischhauer,
  • Nicolaus Kröger,
  • Liesbeth C. de Wreede,
  • Maximilian Christopeit

DOI
https://doi.org/10.3324/haematol.2023.283175
Journal volume & issue
Vol. 109, no. 2

Abstract

Read online

Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.